|
Gene: CASP2 |
Gene summary for CASP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CASP2 | Gene ID | 835 |
Gene name | caspase 2 | |
Gene Alias | CASP-2 | |
Cytomap | 7q34 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | D3DXD9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
835 | CASP2 | LZE4T | Human | Esophagus | ESCC | 6.86e-03 | 1.12e-01 | 0.0811 |
835 | CASP2 | LZE7T | Human | Esophagus | ESCC | 6.48e-04 | 4.12e-01 | 0.0667 |
835 | CASP2 | LZE20T | Human | Esophagus | ESCC | 5.25e-03 | 1.46e-01 | 0.0662 |
835 | CASP2 | LZE24T | Human | Esophagus | ESCC | 1.97e-08 | 1.93e-01 | 0.0596 |
835 | CASP2 | P1T-E | Human | Esophagus | ESCC | 6.87e-03 | 1.66e-01 | 0.0875 |
835 | CASP2 | P2T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.23e-01 | 0.1177 |
835 | CASP2 | P4T-E | Human | Esophagus | ESCC | 8.69e-15 | 3.03e-01 | 0.1323 |
835 | CASP2 | P5T-E | Human | Esophagus | ESCC | 2.93e-15 | 2.69e-01 | 0.1327 |
835 | CASP2 | P8T-E | Human | Esophagus | ESCC | 2.20e-17 | 3.02e-01 | 0.0889 |
835 | CASP2 | P9T-E | Human | Esophagus | ESCC | 3.60e-02 | 1.44e-01 | 0.1131 |
835 | CASP2 | P10T-E | Human | Esophagus | ESCC | 1.23e-20 | 2.96e-01 | 0.116 |
835 | CASP2 | P12T-E | Human | Esophagus | ESCC | 5.79e-16 | 3.41e-01 | 0.1122 |
835 | CASP2 | P15T-E | Human | Esophagus | ESCC | 6.77e-21 | 4.34e-01 | 0.1149 |
835 | CASP2 | P16T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.53e-01 | 0.1153 |
835 | CASP2 | P20T-E | Human | Esophagus | ESCC | 6.12e-03 | 9.55e-02 | 0.1124 |
835 | CASP2 | P21T-E | Human | Esophagus | ESCC | 6.48e-12 | 2.58e-01 | 0.1617 |
835 | CASP2 | P22T-E | Human | Esophagus | ESCC | 8.54e-10 | 1.63e-01 | 0.1236 |
835 | CASP2 | P23T-E | Human | Esophagus | ESCC | 2.02e-03 | 1.30e-01 | 0.108 |
835 | CASP2 | P24T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.57e-01 | 0.1287 |
835 | CASP2 | P26T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.82e-01 | 0.1276 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00380346 | Oral cavity | OSCC | signal transduction in absence of ligand | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00971926 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway in absence of ligand | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00712605 | Oral cavity | OSCC | cellular response to mechanical stimulus | 52/7305 | 81/18723 | 3.86e-06 | 4.55e-05 | 52 |
GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
GO:00315704 | Oral cavity | OSCC | DNA integrity checkpoint | 72/7305 | 123/18723 | 8.77e-06 | 9.31e-05 | 72 |
GO:000961210 | Oral cavity | OSCC | response to mechanical stimulus | 115/7305 | 216/18723 | 1.43e-05 | 1.44e-04 | 115 |
GO:003033018 | Oral cavity | OSCC | DNA damage response, signal transduction by p53 class mediator | 46/7305 | 72/18723 | 1.66e-05 | 1.64e-04 | 46 |
GO:00000774 | Oral cavity | OSCC | DNA damage checkpoint | 67/7305 | 115/18723 | 2.20e-05 | 2.08e-04 | 67 |
GO:00447744 | Oral cavity | OSCC | mitotic DNA integrity checkpoint | 52/7305 | 85/18723 | 2.86e-05 | 2.64e-04 | 52 |
GO:00447734 | Oral cavity | OSCC | mitotic DNA damage checkpoint | 50/7305 | 81/18723 | 2.87e-05 | 2.64e-04 | 50 |
GO:004352310 | Oral cavity | OSCC | regulation of neuron apoptotic process | 111/7305 | 212/18723 | 5.12e-05 | 4.27e-04 | 111 |
GO:004352518 | Oral cavity | OSCC | positive regulation of neuron apoptotic process | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:00069196 | Oral cavity | OSCC | activation of cysteine-type endopeptidase activity involved in apoptotic process | 47/7305 | 78/18723 | 1.16e-04 | 8.42e-04 | 47 |
GO:00315717 | Oral cavity | OSCC | mitotic G1 DNA damage checkpoint | 22/7305 | 30/18723 | 1.43e-04 | 1.01e-03 | 22 |
GO:00448197 | Oral cavity | OSCC | mitotic G1/S transition checkpoint | 22/7305 | 31/18723 | 3.11e-04 | 1.94e-03 | 22 |
GO:20000455 | Oral cavity | OSCC | regulation of G1/S transition of mitotic cell cycle | 74/7305 | 142/18723 | 1.01e-03 | 5.24e-03 | 74 |
GO:19028064 | Oral cavity | OSCC | regulation of cell cycle G1/S phase transition | 84/7305 | 168/18723 | 2.38e-03 | 1.05e-02 | 84 |
GO:00069773 | Oral cavity | OSCC | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:0097193110 | Oral cavity | LP | intrinsic apoptotic signaling pathway | 146/4623 | 288/18723 | 9.76e-22 | 2.78e-19 | 146 |
GO:2001233110 | Oral cavity | LP | regulation of apoptotic signaling pathway | 168/4623 | 356/18723 | 1.35e-20 | 3.02e-18 | 168 |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa0421019 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa0421026 | Oral cavity | LP | Apoptosis | 65/2418 | 136/8465 | 1.33e-06 | 1.48e-05 | 9.53e-06 | 65 |
hsa0421036 | Oral cavity | LP | Apoptosis | 65/2418 | 136/8465 | 1.33e-06 | 1.48e-05 | 9.53e-06 | 65 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CASP2 | SNV | Missense_Mutation | c.23N>T | p.Ser8Phe | p.S8F | P42575 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
CASP2 | SNV | Missense_Mutation | novel | c.905N>G | p.Asn302Ser | p.N302S | P42575 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-A2-A4RY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
CASP2 | insertion | In_Frame_Ins | novel | c.553_554insAAACACACTTCCAGCTGGTGAGTTTTTGCATAA | p.Leu190_Ala191insValSerPheCysIleLysThrHisPheGlnLeu | p.L190_A191insVSFCIKTHFQL | P42575 | protein_coding | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
CASP2 | SNV | Missense_Mutation | c.249N>C | p.Gln83His | p.Q83H | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CASP2 | SNV | Missense_Mutation | rs139233385 | c.794N>A | p.Arg265Gln | p.R265Q | P42575 | protein_coding | tolerated(0.28) | benign(0.011) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CASP2 | insertion | Frame_Shift_Ins | novel | c.3_4insGCGGC | p.Pro4ArgfsTer16 | p.P4Rfs*16 | P42575 | protein_coding | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | ||
CASP2 | SNV | Missense_Mutation | rs756201685 | c.907N>A | p.Ala303Thr | p.A303T | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CASP2 | SNV | Missense_Mutation | rs144817015 | c.464N>A | p.Arg155His | p.R155H | P42575 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CASP2 | SNV | Missense_Mutation | rs141615673 | c.718G>A | p.Val240Ile | p.V240I | P42575 | protein_coding | deleterious(0.05) | benign(0.029) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CASP2 | SNV | Missense_Mutation | rs370097426 | c.814N>A | p.Val272Met | p.V272M | P42575 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL197672 | EMRICASAN | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252166828 | ||
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | CETYLPYRIDINIUM CHLORIDE | CETYLPYRIDINIUM CHLORIDE | 18366176 | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | SPERMINE | SPERMINE | 18366176 | |
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178101981 | ||
835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | N-DECYLBUTYRAMIDE | CHEMBL265439 | 18366176 |
Page: 1 |